RxDoctor Payments Data

Olga Voroshilova, MD

Nephrology · Akron, OHNPI 1447248794

Payments from drug & device makers

$1,166in general payments, 2019–2025

Across 47 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$295
  • W. L. Gore & Associates, Inc.$213
  • Otsuka America Pharmaceutical, Inc.$150
  • AstraZeneca$138
  • Mallinckrodt Hospital Products Inc.$74
  • Novartis$73
  • plus $223 from 7 others

What the payments were for

  • Food & beverage$1,13597%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,166 in reported general payments places this provider in the 50th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$126,771
Medicare patients
411
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide25$98,526
FarxigaDapagliflozin Propanediol51$37,708
Sevelamer Carbonate105$28,330
LokelmaSodium Zirconium Cyclosilicate12$10,920
Calcium Acetate17$1,970
Midodrine Hcl34$1,396
Calcitriol94$917
Losartan Potassium88$744
Torsemide38$575
Carvedilol51$402
Valsartan24$383
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid24$335
Nebivolol Hcl11$330
Metolazone27$328
Amlodipine Besylate89$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$52$98,52625 claims
AstraZenecaFarxiga, Lokelma$138$48,62963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 450 nephrology providers in Ohio.

Other nephrology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →